Oct 21 (Reuters) - Laboratory operator Quest Diagnostics ( DGX )

raised its full-year forecast for profit and revenue on

Tuesday, banking on robust demand for its diagnostic tests.

Shares of the New Jersey-based company were up 2.7% in

premarket trading.

Quest expects 2025 adjusted profit between $9.76 and $9.84

per share versus its previous range of $9.63 to $9.83 per share.

It sees annual revenue at $10.96 billion to $11 billion,

above its prior view of $10.80 billion to $10.92 billion.

While healthy demand for non-urgent surgeries, particularly

among older Americans, has driven increased demand for

diagnostic checkups, companies like Quest and Labcorp ( LH )

have also benefited from deals to manage hospital labs as they

seek market share gains.

Quest's revenue for the third quarter rose 13.1% to $2.82

billion, beating analysts' average estimate of $2.74 billion,

according to data compiled by LSEG.

The company said it expects new legislation, including the

Trump administration's One Big Beautiful Bill Act, and the

scheduled expiration of enhanced Affordable Care Act tax credits

at the end of 2025, to not have a material impact on revenue in

2025 and 2026.

The changes could trim consolidated revenue by up to 50-60

basis points by 2028 compared with 2025, mainly due to lower

Obamacare or ACA exchange insurance plan revenue.

The OBBBA imposes stricter eligibility verification and ends

automatic re-enrollment for ACA customers, while the lapse of

enhanced tax credits will raise premiums for millions of

enrollees.

On an adjusted basis, Quest posted a profit of $2.60 per

share for the quarter ended September 30, above analysts'

average estimate of $2.50.